This study presents an optimized CRISPR-Cas12a system for large-scale genetic screening, revealing critical genes involved in lymphoma development and therapy.

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume. They also have a ...

By treating DNA as a language, Brian Hie’s “ChatGPT for genomes” could pick up patterns that humans can’t see, accelerating ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.